Research & Innovation Published on April 28, 2025

2024 Discovery: How GLP-1 Acts in the Brain

1 min read

A team of researchers from UT Southwestern Medical Center published a major discovery in August 2024 in the journal Science on the mechanism of action of GLP-1 drugs.

THE DISCOVERY

Scientists identified a specific subset of brain cells whose activation would be partially responsible for the effects of weight loss drugs like semaglutide (Ozempic, Wegovy).

WHY IT MATTERS

Until now, the precise mechanism by which GLP-1 agonists induce weight loss was not fully understood. It was known that they:

Slow gastric emptying
Reduce appetite
Act on the pancreas

This discovery reveals a central (brain) mechanism that explains the remarkable effectiveness of these treatments.

IMPLICATIONS FOR RESEARCH

These results could allow:

Optimization of existing drug efficacy
Development of more targeted molecules
Potential reduction of side effects
Better understanding of satiety mechanisms

CONTEXT

GLP-1 drugs represent a therapeutic revolution. Semaglutide generated over $20 billion in sales in 2024. Understanding precisely how they work is crucial for improving future treatments.

This research illustrates the importance of fundamental science in the development of peptide therapies.